Across TCGA pan-cancer cohorts, RPF2P1 RNA is linked to patient survival in 24 of 34 cancer types, making it the most broadly survival-associated RPF2P1 data layer.
The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where higher RPF2P1 RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated RPF2P1 expression acts as an unfavorable survival marker, although some lineages such as UCS and CESC show a favorable association.
KIRC, UCS, and MESO are the cancer types where RPF2P1 RNA most reproducibly stratifies survival.
RNA survival associations by lineage
Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.